Atea Pharmaceuticals starts Phase 1 trial of AT-587 for hepatitis E

July 14, 2026 7:00 AM

Atea Pharmaceuticals (Nasdaq: AVIR) has initiated a first-in-human Phase 1 clinical trial of AT-587, an oral antiviral nucleotide analog being ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found